INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 431m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
SEC FORM 4/Other acquisition or dispositionVerified data

Horich William Todd reported SUPN

SVP, Commercial Operations · SUPERNUS PHARMACEUTICALS, INC. · SUPERNUS PHARMACEUTICALS, INC. — Employee Stock Option (Right to Buy)

Side
J
Value
—
Shares
13.0K
Price
—
Executed
Nov 2, 2026
Disclosed
Nov 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 4, 2026 disclosed

SUPN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type+3 / 20

    Other acquisition or disposition

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SUPN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    12
    RJ
    Rubin JonathanSVP, Chief Medical Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    15.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RJ
    Rubin JonathanSVP, Chief Medical Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    20.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    8
    SB
    Sensenig BethanyDirector
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    24.2K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RJ
    Rubin JonathanSVP, Chief Medical Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    14.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RJ
    Rubin JonathanSVP, Chief Medical Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    25.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RJ
    Rubin JonathanSVP, Chief Medical Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    25.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KA
    Khattar Jack A.Director, President, CEO
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    250.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KA
    Khattar Jack A.Director, President, CEO
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    280.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    8
    SB
    Sensenig BethanyDirector
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    2,989 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BP
    Bhatt Padmanabh P.Sr. VP of IP, CSO
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    15.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BP
    Bhatt Padmanabh P.Sr. VP of IP, CSO
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    20.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BP
    Bhatt Padmanabh P.Sr. VP of IP, CSO
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    13.5K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RJ
    Rubin JonathanSVP, Chief Medical Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    3,500 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    MF
    Mottola FrankSVP, Chief Tech. Ops. Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    14.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    MF
    Mottola FrankSVP, Chief Tech. Ops. Officer
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    20.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BC
    Barlow CarroleeDirector
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    6,293 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BC
    Barlow CarroleeDirector
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    8,252 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BC
    Barlow CarroleeDirector
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    4,977 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KA
    Khattar Jack A.Director, President, CEO
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    322.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    HM
    Hudson Frederick M.Director
    SUPNSUPERNUS PHARMACEUTICALS, INC.
    Other acquisition or disposition
    		J—
    6,036 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002117599-26-000009
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 2, 2026
    Published
    Nov 4, 2026
    Ingested by INSIDER
    Nov 4, 22:39 UTC
    Last re-read
    Nov 5, 21:23 UTC

    Extracted facts

    Filer
    Horich William Todd
    Role
    SVP, Commercial Operations
    Transaction
    Other acquisition or dispositionAs filed: “J”
    Asset
    SUPERNUS PHARMACEUTICALS, INC. — Employee Stock Option (Right to Buy)
    Ticker
    SUPN
    Shares
    13.0K
    Price per share
    $0
    Execution date (reported)
    Nov 2, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    2

    What this establishes

    Horich William Todd filed this Form 4 reporting a other acquisition or disposition of SUPN on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, Commercial Operations
    Horich William Toddcik:0002117599
    Issuer
    SUPERNUS PHARMACEUTICALS, INC.cik:0001356576

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.